MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464048 | Name: Formoterol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Formoterol HCl is a long-acting beta-2 adrenergic agonist (LABA).

Chemical Structure

Formoterol HCl
Formoterol HCl
CAS#1254710-01-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 464048

Name: Formoterol HCl

CAS#: 1254710-01-4 (HCl)

Chemical Formula: C19H25ClN2O4

Exact Mass: 380.1503

Molecular Weight: 380.87

Elemental Analysis: C, 59.92; H, 6.62; Cl, 9.31; N, 7.36; O, 16.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1254575-18-2 (maleate) 1254710-01-4 (HCl) 200815-49-2 (tartrate)
Synonym
Formoterol HCl; Arformoterol HCl; (R,R)-Formoterol hydrochloride; (R,R)-Formoterol HCl
IUPAC/Chemical Name
N-(2-hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide hydrochloride
InChi Key
VBOQGHUYFLYKOQ-QVRIGTRMSA-N
InChi Code
InChI=1S/C19H24N2O4.ClH/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1H/t13-,19+;/m1./s1
SMILES Code
O=CNC1=CC([C@@H](O)CN[C@H](C)CC2=CC=C(OC)C=C2)=CC=C1O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 380.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liang Y, Chen M, Tan C, Tu C, Zheng X, Liu J. Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate. Int J Gen Med. 2021 Feb 4;14:357-359. doi: 10.2147/IJGM.S291695. PMID: 33568936; PMCID: PMC7869710. 2: FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Larsdotter U, Emerath U, Jansen G, Puu M, Alagappan VKT, Surmont F, Reddel HK. Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Saf. 2021 Feb 6. doi: 10.1007/s40264-020-01041-z. Epub ahead of print. PMID: 33548020. 3: Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C. Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021 Jan 28;16:179-189. doi: 10.2147/COPD.S286087. PMID: 33542624; PMCID: PMC7851632. 4: Richeldi L, Piraino A, Macagno F, Micarelli G, Ingrassia E. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol. Int J Chron Obstruct Pulmon Dis. 2021 Jan 27;16:159-166. doi: 10.2147/COPD.S286559. PMID: 33536751; PMCID: PMC7850441. 5: Pisi R, Aiello M, Piraino A, Paleari D, Frizzelli A, Bertorelli G, Chetta A. Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients. Pulm Ther. 2021 Feb 4. doi: 10.1007/s41030-021-00144-x. Epub ahead of print. PMID: 33538996. 6: Hatter L, Bruce P, Braithwaite I, Holliday M, Fingleton J, Weatherall M, Beasley R. ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021 Jan 25;7(1):00701-2020. doi: 10.1183/23120541.00701-2020. PMID: 33532465; PMCID: PMC7836558. 7: García G, Bergna M, Vásquez JC, Cano Salas MC, Miguel JL, Celis Preciado C, Acuña Izcaray A, Barros Monge M, García Batista N, Zabert I, Mayorga JL, Casanova Mendoza R, Gutierrez M, Montero Arias MF, Urtecho Perez L, Antúnez M, Williams Derby V, Villatoro Azméquita A, Motiño L, De Oliveira MA, Rey Sanchez D, Arroyo M, Rodriguez M. Severe asthma: adding new evidence - Latin American Thoracic Society. ERJ Open Res. 2021 Jan 18;7(1):00318-2020. doi: 10.1183/23120541.00318-2020. PMID: 33532459; PMCID: PMC7836469. 8: Reddel HK. Updated Australian guidelines for mild asthma: what's changed and why? Aust Prescr. 2020 Dec;43(6):220-224. doi: 10.18773/austprescr.2020.076. Epub 2020 Dec 1. PMID: 33363311; PMCID: PMC7738702. 9: Cruz ÁA, Barile S, Nudo E, Brogelli L, Guller P, Papi A. ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy. Asthma Res Pract. 2021 Jan 29;7(1):1. doi: 10.1186/s40733-021-00067-z. PMID: 33514439; PMCID: PMC7844897. 10: Usmani OS, Roche N, Jenkins M, Stjepanovic N, Mack P, De Backer W. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence. Int J Chron Obstruct Pulmon Dis. 2021 Jan 18;16:113-124. doi: 10.2147/COPD.S274846. PMID: 33500616; PMCID: PMC7822085. 11: Roche N, Aguilaniu B, Paternotte S, Dallery N. Real-life association between inhaler technique, patient preference and asthma control in patients with uncontrolled asthma switched to budesonide/formoterol DuoResp® Spiromax® combination. J Asthma. 2021 Feb 13:1-10. doi: 10.1080/02770903.2021.1875482. Epub ahead of print. PMID: 33493074. 12: Zhudenkov K, Palmér R, Jauhiainen A, Helmlinger G, Stepanov O, Peskov K, Eriksson UG, Wählby Hamrén U. Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling. Int J Chron Obstruct Pulmon Dis. 2021 Jan 15;16:101-111. doi: 10.2147/COPD.S284720. PMID: 33488073; PMCID: PMC7815071. 13: Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2021 Jan 14;16:79-89. doi: 10.2147/COPD.S291030. PMID: 33488071; PMCID: PMC7814657. 14: Papi A, Virchow JC, Singh D, Kots M, Vele A, Georges G, Canonica. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post- hoc analyses. J Allergy Clin Immunol. 2021 Jan 21:S0091-6749(21)00086-5. doi: 10.1016/j.jaci.2021.01.007. Epub ahead of print. PMID: 33485959. 15: Wong HS, Guo CL, Lin GH, Lee KY, Okada Y, Chang WC. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy. Genomics. 2021 Jan 20;113(2):564-575. doi: 10.1016/j.ygeno.2020.12.041. Epub ahead of print. PMID: 33482326; PMCID: PMC7817445. 16: Kaplan A. The Myth of Mild: Severe Exacerbations in Mild Asthma: An Underappreciated, but Preventable Problem. Adv Ther. 2021 Jan 20:1–13. doi: 10.1007/s12325-020-01598-2. Epub ahead of print. PMID: 33474708; PMCID: PMC7816833. 17: Expanded table: Correct use of inhalers for asthma. Med Lett Drugs Ther. 2020 Dec 14;62(1613):e204-e208. PMID: 33446624. 18: Expanded table: Some inhaled drugs for treatment of asthma. Med Lett Drugs Ther. 2020 Dec 14;62(1613):e200-e203. PMID: 33446623. 19: Drugs for asthma. Med Lett Drugs Ther. 2020 Dec 14;62(1613):193-200. PMID: 33446622. 20: Pohunek P, Varoli G, Reznichenko Y, Mokia-Serbina S, Brzostek J, Kostromina V, Kaladze M, Muraro A, Carzana E, Armani S, Kaczmarek J. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study. Eur J Pediatr. 2021 Jan 6. doi: 10.1007/s00431-020-03888-x. Epub ahead of print. PMID: 33404895.

View History

PTX80

PTX80